Drug Selectivity
«In summary, this is a very good and valuable book for graduate students as well as medicinal chemists in academia and pharmaceutical companies. Readers will find many interesting chapters, some of which are more oriented to experts, while others are well suited for beginners. I recommend this book to those working in the field of medicinal chemistry, or even pharmacology, who have a particular interest in selective and selectively nonselective drugs. (Prof. Antonio Macchiarulo, ChemMedChem 19/2018)»
The book "Drug Selectivity - An Evolving Concept in Medicinal Chemistry" provides a current overview and comprehensive compilation for medicinal chemists that discusses the effects of aiming for multiple targets on the entire drug development process. Les mer
The result is a broad survey of current and future strategies for drug selectivity in medicinal chemistry with theoretical but also practical aspects. Different strategies are presented and evaluated, such as various design approaches, merged multiple ligands, discovery technologies and a broad range of successful examples of unselective drugs taken from all major disease areas. With its wide-ranging view of an emerging new paradigm in drug development, this handbook is of prime importance for every medicinal and pharmaceutical chemist.
Detaljer
- Forlag
- Wiley-VCH Verlag GmbH
- Språk
- Engelsk
- ISBN
- 9783527674411
- Utgivelsesår
- 2017
- Format
- Kopibeskyttet PDF (Må leses i Adobe Digital Editions)
Om forfatteren
Helmut Buschmann has a PhD in organic chemistry from Aachen University and extensive industrial experience in medicinal chemistry, drug discovery and development, scale-up, pharmaceutical development, CMC, patent filing and prosecution. Helmut has over 25 years of international experience in drug discovery research and drug development in the pharmaceutical/biotechnology sectors, both in industry and academia. During his career he worked with a broad range of different targets in different therapeutic areas from pain research to anti-infectives. He has a long publication and patent record, being an author/co-author in more than 150 scientific publications, editor of various reference books and is a named inventor/co-inventor in more than 250 patent applications.
As a result of his research activities more than 15 NCEs within different therapeutic areas have entered the clinical phase (e.g. Rosonabant, Cizorlitine, Dulopetine, Axamadol,). Some of them have reached clinical phase III or are marketed (e.g. Tapentadol: Nucynta? Palexia?). Currently, he is Head of Chemistry, Pharmaceutical Development and Patent A_ airs at AiCuris, Wuppertal and cofounder and co-owner of RD&C Research, Development & Consulting in Vienna.
Anmeldelser
«In summary, this is a very good and valuable book for graduate students as well as medicinal chemists in academia and pharmaceutical companies. Readers will find many interesting chapters, some of which are more oriented to experts, while others are well suited for beginners. I recommend this book to those working in the field of medicinal chemistry, or even pharmacology, who have a particular interest in selective and selectively nonselective drugs. (Prof. Antonio Macchiarulo, ChemMedChem 19/2018)»